This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

The 5 Dumbest Things on Wall Street This Week: March 8

3.) Impax Ineptitude

Come on, Impax (IPXL). Clean up your act already!

The generic drug maker revealed this week that the Food and Drug Administration found 12 so-called "observations" -- three of which were repeat problems -- at its U.S. manufacturing plant in Hayward, Calif. The news sent the company's shares tumbling over 26% Tuesday.

"We have committed significant resources in our efforts to meet FDA requirements and are clearly disappointed by this news," said Impax Chief Executive Officer Larry Hsu in a statement. "Resolving the FDA concerns remains a top priority and we intend to complete this work as quickly as possible." The company said it will respond to the FDA within 15 business days, as required by law.

Sorry Hsu, but that's just silly. How can you fail a plant inspection for a second time? Did you not pay attention to the quality problems that undid former Johnson & Johnson (JNJ) CEO Bill Weldon?

Heck, most teenagers are smart enough to straighten up their rooms immediately after their parents threaten to take away the car keys! How lazy can you be?

Meanwhile, Hsu's slip-up is all the more serious because the approval of its Parkinson's drug Rytary is at stake. The FDA mandated a re-inspection of the Hayward plant after it rejected Rytary in January. If the drug is approved, Impax will sell Rytary in the U.S. and Taiwan while GlaxoSmithKline (GSK) will hawk it throughout the rest of the world.

That said, all hope is not lost, says Piper Jaffray analyst David Amsellem. Despite the stock's shellacking to $15 a share, he is keeping his "Overwright" rating based on the belief that battered Impax is now take-out bait.

"We would caution against an overreaction given our view that a possible sale of the company is a realistic alternative toward unlocking the considerable value of the generics pipeline and Rytary. Given the strong cash position (near $9 per share by late 2014) and a restive shareholder base, we believe an evaluation of strategic alternatives is a real possibility," opines Amsellem.

We're not so sure Dave. Those "restive" shareholders probably unloaded their shares in this latest selloff, putting your $27 price target well out of reach even if there is a buyout offer.

And as for the possibility of such a "strategic" alternative even taking place, considering the current status of the Hayward facility, well, we have a better alternative for Hsu if he survives this embarrassing episode: Fix your damn plant!

Stock quotes in this article: GRPN, GOOG, TUES, IPXL, SOHU, JCP, VNO, XIN, HGSH, JNJ, GSK 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,424.85 +162.29 1.00%
S&P 500 1,862.31 +19.33 1.05%
NASDAQ 4,086.2250 +52.0640 1.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs